Table 1.
Ongoing clinical trials targeting autophagy/lysosome in pancreatic ductal adenocarcinoma (PDAC).
| Disease | Trial Phase | Therapy | NCT No. |
|---|---|---|---|
| Metastatic | I | GnP + HCQ + Ipilimumab (anti-CTLA4 antibody) | NCT04787991 |
| Metastatic | I/II | Cobimetinib (MEK inhibitor) + HCQ + Atezolizumab (anti-PDL1 antibody) | NCT04214418 |
| Unresectable | I | Trametinib (MEK inhibitor) + HCQ | NCT03825289 |
| Metastatic | I | Binimetinib (MEK inhibitor) + HCQ | NCT04132505 |
| Unresectable | I | Ulixertinib (ERK inhibitor) + HCQ | NCT04145297 |
| Metastatic | II | LY3214996 (ERK inhibitor) + HCQ | NCT04386057 |
| Unresectable | I | mFOLFIRINOX + HCQ + Chlorphenesin Carbamate | NCT05083780 |
| Unresectable | II | GnP + HCQ + Paricalcitol (Vitamin D receptor agonist) | NCT04524702 |
| Resectable (neoadjuvant) | I | HCQ + Paricalcitol (Vitamin D receptor agonist) + Losartan. Used after neoadjuvant mFOLFIRINOX + RT and prior to surgery. | NCT05365893 |
| Unresectable and borderline resectable | II | Gem + Cisplatin + Paclitaxel protein bound + HCQ | NCT04669197 |
| Resectable (neoadjuvant) | I/II | mFOLFIRINOX + HCQ | NCT04911816 |
GnP, gemcitabine + nab-paclitaxel; RT, radiation therapy.